Press Releases

Month Year

Month Year

Jul 2, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jun 26, 2019

Insmed Announces Closing of Public Offering of Common Stock

Read more
Jun 6, 2019

Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

Read more
Jun 4, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
May 24, 2019

Insmed Announces Closing of Public Offering of Common Stock

Read more
May 21, 2019

Insmed Announces Pricing of Public Offering of Common Stock

Read more
May 20, 2019

Insmed Announces Proposed Public Offering of Common Stock

Read more
May 20, 2019

New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease

--ARIKAYCE Plus Guideline-Based Therapy (GBT) Associated with Significantly Higher Rates of Sustained Culture Conversion on Therapy and Durable Culture Conversion Three Months Post-Treatment Compared with GBT Alone--

Read more
May 7, 2019

Insmed Reports First Quarter 2019 Financial Results and Provides Business Update

-- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 --

Read more
Apr 30, 2019

Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation